Compare Stocks: CTMX, IMNM, ZLAB, and NAMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.82 +1.8%	$3.39	$1.94 ▼ $8.21	$602.49M	2.14	3.56 million shs	4.21 million shs
IMNM Immunome	$23.93 +2.0%	$25.32	$9.06 ▼ $30.06	$2.66B	2.13	895,447 shs	890,752 shs
NAMS NewAmsterdam Pharma	$21.93 +3.5%	$27.46	$21.02 ▼ $42.21	$2.53B	0.09	1.29 million shs	2.31 million shs
ZLAB Zai Lab	$25.81 +4.6%	$23.11	$15.96 ▼ $34.72	$2.81B	0.83	886,063 shs	673,110 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+1.81%	-15.82%	-16.81%	-4.41%	+46.11%
IMNM Immunome	+2.00%	-4.16%	-13.17%	+27.69%	+166.18%
NAMS NewAmsterdam Pharma	+3.54%	+0.32%	-19.52%	-26.48%	-10.45%
ZLAB Zai Lab	+4.62%	+6.79%	+0.94%	+41.97%	-20.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.82 +1.8%	$3.39	$1.94 ▼ $8.21	$602.49M	2.14	3.56 million shs	4.21 million shs
IMNM Immunome	$23.93 +2.0%	$25.32	$9.06 ▼ $30.06	$2.66B	2.13	895,447 shs	890,752 shs
NAMS NewAmsterdam Pharma	$21.93 +3.5%	$27.46	$21.02 ▼ $42.21	$2.53B	0.09	1.29 million shs	2.31 million shs
ZLAB Zai Lab	$25.81 +4.6%	$23.11	$15.96 ▼ $34.72	$2.81B	0.83	886,063 shs	673,110 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+1.81%	-15.82%	-16.81%	-4.41%	+46.11%
IMNM Immunome	+2.00%	-4.16%	-13.17%	+27.69%	+166.18%
NAMS NewAmsterdam Pharma	+3.54%	+0.32%	-19.52%	-26.48%	-10.45%
ZLAB Zai Lab	+4.62%	+6.79%	+0.94%	+41.97%	-20.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	321.99% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	44.74% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	126.75% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	44.32% Upside

Current Analyst Ratings Breakdown

Latest CTMX, IMNM, ZLAB, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $45.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
7/29/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	8.06	N/A	N/A	$0.58 per share	4.86
IMNM Immunome	N/A	N/A	N/A	N/A	$5.75 per share	N/A
NAMS NewAmsterdam Pharma	$22.50M	116.51	N/A	N/A	$5.97 per share	3.67
ZLAB Zai Lab	$460.16M	6.38	N/A	N/A	$6.39 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest CTMX, IMNM, ZLAB, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
IMNM Immunome	N/A	15.08	15.08
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
IMNM Immunome	44.58%
NAMS NewAmsterdam Pharma	89.89%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
IMNM Immunome	7.21%
NAMS NewAmsterdam Pharma	12.74%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

CTMX, IMNM, ZLAB, and NAMS Headlines

Recent News About These Companies

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Seven Fleet Capital Management LP Acquires 58,158 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

September 5, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Down 4.6% - Here's What Happened

September 4, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Up 6.9% - Still a Buy?

September 2, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR $ZLAB Stock Position Boosted by Headlands Technologies LLC

September 1, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares

July 2, 2026 | insidertrades.com

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, IMNM, ZLAB, and NAMS Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.82 +0.05 (+1.81%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$2.82 +0.00 (+0.14%)

As of 07:00 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$23.93 +0.47 (+2.00%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$24.31 +0.38 (+1.58%)

As of 04:00 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

NewAmsterdam Pharma NASDAQ:NAMS

$21.93 +0.75 (+3.54%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$22.55 +0.62 (+2.85%)

As of 07:05 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Zai Lab NASDAQ:ZLAB

$25.81 +1.14 (+4.62%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$26.08 +0.27 (+1.03%)

As of 07:04 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, IMNM, ZLAB, and NAMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, IMNM, ZLAB, and NAMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, IMNM, ZLAB, and NAMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, IMNM, ZLAB, and NAMS Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Immunome NASDAQ:IMNM

NewAmsterdam Pharma NASDAQ:NAMS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, IMNM, ZLAB, and NAMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, IMNM, ZLAB, and NAMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, IMNM, ZLAB, and NAMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, IMNM, ZLAB, and NAMS Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Immunome NASDAQ:IMNM

NewAmsterdam Pharma NASDAQ:NAMS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools